Zymeworks is a global biotechnology company that develops multifunctional biotherapeutic candidates and manages a portfolio of licensed healthcare assets for difficult-to-treat cancers, inflammation, and autoimmune diseases. The company generates revenue through strategic partnerships that include upfront payments, development and commercial milestones, and royalties on licensed therapies, while leveraging proprietary platforms such as Azymetric for bispecific antibodies and drug conjugate technologies to advance its own clinical pipeline. Zymeworks employs an asset and royalty aggregation strategy designed to create durable, predictable cash flows from partnered programs and its own candidates while maintaining capital discipline and flexibility to return capital to shareholders.